Drugs / AVX601
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT00439803 Comparator | Apr 2007 → Jul 2008 | cytomegalovirus infection | AlphaVax, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AVX601 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00439803 ↗ |
| Modality | Vaccine | “AVX601, a bivalent alphavirus replicon vaccine expressing three CMV proteins (gB, pp65 and IE1) is a candidate vaccine against cytomegalovirus (CMV).” NCT00439803 ↗ |
| Route | Intramuscular | “via the IM route” NCT00439803 ↗ |